Harness Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
26
- Latest Deal Type
-
Series 1
- Investors
-
6
Harness Therapeutics General Information
Description
Developer of a biotechnology platform designed to help the physiological upregulation of important neurodegenerative targets. The company utilizes mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis and deliver disease-modifying therapeutics for neurodegenerative diseases, enabling patients to achieve precise protein regulation and address conditions such as Huntington's disease and ALS/AD.
Contact Information
Website
www.harnesstx.comCorporate Office
- Minverva Building 250
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Minverva Building 250
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Harness Therapeutics Timeline
Harness Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Early Stage VC (Series 1) | 20-Jan-2025 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 01-Dec-2023 | Completed | Pre-Clinical Trials | |||
| 3. Seed Round | 05-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 28-Jan-2020 | $11.9M | $11.9M | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
Harness Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preferred Shares | ||||||||
| Preferred Shares | ||||||||
| Preferred Shares | 1,500 | $0.013342 | $1334.19 | $1334.19 | $1334.19 | 8.4% | ||
| Preferred Shares | 1,236 | $0.013342 | $1187.39 | $1187.39 | $1187.39 | 6.92% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Harness Therapeutics Comparisons
Industry
Financing
Details
Harness Therapeutics Competitors (5)
One of Harness Therapeutics’s 5 competitors is LoQus23 Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| LoQus23 Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Rgenta Therapeutics | Venture Capital-Backed | Woburn, MA | ||||
| WaVe Life Sciences | Formerly VC-backed | Cambridge, MA | ||||
| CAMP4 | Formerly VC-backed | Cambridge, MA | ||||
| Stoke Therapeutics | Formerly VC-backed | Bedford, MA |
Harness Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Harness Therapeutics Patents
Harness Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202507056-D0 | Fan1 targeting agents | Pending | 08-May-2025 | ||
| GB-202507057-D0 | Fan1 targeting agents | Pending | 08-May-2025 | ||
| WO-2026234385-A1 | Fan1 targeting agents | Pending | 08-May-2025 | ||
| GB-202403511-D0 | Functional nucleic acid | Inactive | 11-Mar-2024 | ||
| GB-202401412-D0 | Functional nucleic acid | Inactive | 02-Feb-2024 | C12N15/1137 |
Harness Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Harness Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ono Venture Investment | Corporate Venture Capital | Minority | ||
| Takeda Ventures | Corporate Venture Capital | Minority | ||
| Epidarex Capital | Venture Capital | Minority | ||
| SV Health Investors | PE/Buyout | Minority | ||
| Takeda Pharmaceutical | Corporation | Minority |
Harness Therapeutics FAQs
-
When was Harness Therapeutics founded?
Harness Therapeutics was founded in 2020.
-
Where is Harness Therapeutics headquartered?
Harness Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Harness Therapeutics?
Harness Therapeutics has 26 total employees.
-
What industry is Harness Therapeutics in?
Harness Therapeutics’s primary industry is Biotechnology.
-
Is Harness Therapeutics a private or public company?
Harness Therapeutics is a Private company.
-
What is Harness Therapeutics’s current revenue?
The current revenue for Harness Therapeutics is .
-
How much funding has Harness Therapeutics raised over time?
Harness Therapeutics has raised $23M.
-
Who are Harness Therapeutics’s investors?
Ono Venture Investment, Takeda Ventures, Epidarex Capital, SV Health Investors, and Takeda Pharmaceutical are 5 of 6 investors who have invested in Harness Therapeutics.
-
Who are Harness Therapeutics’s competitors?
LoQus23 Therapeutics, Rgenta Therapeutics, WaVe Life Sciences, CAMP4, and Stoke Therapeutics are competitors of Harness Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
